Ann: 1AD & GPCR Therapeutics to evaluate CXCR4 i-bodies in cancer, page-3

I was playing with ChatGPT and asked it about Adalta Ltd. It gave a reference to AD-712 as being:

"AD-712 is a drug candidate being developed by Adalta Ltd for the treatment of glioblastoma, which is a type of aggressive brain cancer. Glioblastoma is associated with a poor prognosis, with few effective treatment options currently available.

AD-712 is an i-body drug candidate that targets a protein called CXCR4, which is involved in the progression of glioblastoma. By targeting CXCR4, AD-712 has the potential to inhibit the growth and spread of glioblastoma cells.

Preclinical studies of AD-712 have demonstrated promising results, including the ability to significantly reduce the growth of glioblastoma tumors in mouse models. Adalta is currently working to further develop AD-712 and bring it through clinical trials to evaluate its safety and efficacy in humans.

Overall, AD-712 represents a promising new approach to the treatment of glioblastoma and may provide hope for patients with this devastating disease."

I suspect that it is referring to this collaboration. The molecule has a name and a purpose. That's something!